PRINCETON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Covance Inc. , a leading provider of drug development services, announced today that it entered into a biomarker alliance and services agreement with Rules-Based Medicine, Inc. (RBM), a leading provider of multiplexed protein biomarker testing to the pharmaceutical industry.
“RBM’s unique biomarker technology platform, combined with Covance’s recent acquisitions and alliances in biomarkers and genomics, strengthens our ability to provide comprehensive biomarker discovery, verification, validation, and deployment in both the preclinical and clinical setting,” said Deborah Tanner, Corporate Senior Vice President and President of Covance Central Laboratory Services. “These innovative technologies are critical tools for drug safety and efficacy testing, which help enable our clients to make better decisions and accelerate their drug development programs.”
“Comprehensive, accurate, and reproducible biomarker testing can improve drug development programs by stratifying clinical trial subjects and providing sensitive measurements of drug safety and efficacy,” said Craig Benson, RBM president and chief executive officer. “By leveraging Covance’s market-leading central laboratory and world-class scientific talent, along with RBM’s multiplexing capabilities and broad biomarker menu, we aim to help pharmaceutical and biotechnology companies enhance the effectiveness and success of their clinical trials.”
About Rules-Based Medicine, Inc.
Rules-Based Medicine (RBM) is a CLIA-certified biomarker testing laboratory that solves complex therapeutic development, diagnostic and treatment challenges with innovative products and services. The Company’s proprietary Multi-Analyte Profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes. Building on the MAP platform, RBM has developed a host of solutions including: a self-contained whole-blood culture system that brings reproducibility and simplicity to ex vivo immune response measurement; novel and companion diagnostic tests for complex diseases and therapies; therapeutic-specific MAPs custom designed for late-stage clinical development; and new assays for the early detection of renal damage. More information about RBM is available via the worldwide web at www.rulesbasedmedicine.com.
CONTACT: Media, +1-609-419-2060, or Investors, +1-609-452-4807, both for
Covance
Web site: http://www.covance.com/
